Beam Therapeutics BEAM D&A

D&A at other companies

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Arrowhead ResearchARWR

$6.37M+4.7%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

MGN

MagniteMGNI

$14.56M+19.2%

Wave Life SciencesWVE

$858K-0.8%

Intellia TherapeuticsNTLA

$2.1M-16.0%

FAQ

What is Beam Therapeutics's D&A?

Beam Therapeutics (BEAM) reported D&A of $5.61M in Q1 2026.

How has Beam Therapeutics's D&A changed year-over-year?

Beam Therapeutics's D&A increased by 1.4% year-over-year, from $5.53M to $5.61M.

What is the long-term trend for Beam Therapeutics's D&A?

Over 4 years (2021 to 2025), Beam Therapeutics's D&A has grown at a 31.5% compound annual growth rate (CAGR), from $7.45M to $22.29M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.